Leerink downgraded Karuna Therapeutics (KRTX) to Market Perform from Outperform with a price target of $330, up from $270, as the firm expects the stock to trade based on deal dynamics and no longer on fundamentals after Bristol Myers (BMY) agreed to acquire Karuna for $330 per share. The firm doesn’t believe it’s likely that another player will come in at a higher price and we doesn’t expect FTC pushback, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRTX:
- M & A News: Bristol-Myers (NYSE:BMY) to Acquire Karuna for $14B
- Karuna Therapeutics’ KarXT results in schizophrenia published in The Lancet
- Karuna Therapeutics initiated with bullish view at Citi, here’s why
- Karuna Therapeutics initiated with bullish view at Deutsche Bank, here’s why
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next